Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader $(KOL)$ event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。